**Author details**

Sabina Wiecek Department of Paediatrics, Medical University of Silesia, Katowice, Poland

\*Address all correspondence to: sabinawk@wp.pl

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**87**

10.1002/cld.583

*Liver Changes in the Course of Cystic Fibrosis DOI: http://dx.doi.org/10.5772/intechopen.89306*

[1] Colombo C. Liver disease in cystic fibrosis. Current Opinion in Pulmonary [11] Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Seminars in Liver Disease.

[12] Bartlett J, Friedmann K, Ling S, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;**9**:

[13] Boëlle PY, Debray D, Guillot L, Corvol H, et al. SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genetics in Medicine. 2019;**21**(9):2151-2155. DOI: 10.1038/

Housset C. Modifier genes in cystic fibrosis-related liver disease. Current Opinion in Gastroenterology. 2019 Mar;**35**(2):88-92. DOI: 10.1097/ MOG.0000000000000508

[15] Freudenberg F, Broderick A, Yu B, et al. Pathophysiological basis of liver disease in cystic fibrosis employing a Delta F508 mouse model. American Journal of Physiology-Gastrointestinal and Liver Physiology.

[16] Fustik S, Traikovska M, Jakovska T, et al. Screening for liver disease in cystic

genetic risk factors for its development. The Turkish Journal of Pediatrics.

literature. Transplantation Proceedings. 2019;**51**(3):790-793. DOI: 10.1016/j

[18] Bergheim I, Guo L, Davis M, et al. Critical role of plasminogen activator inhibitor – 1 in cholestasis liver injury and fibrosis. Journal of Pharmacology

fibrosis: Analysis of clinical and

Kaufman SS, et al. Unusual cystic fibrosis transmembrane conductance regulator mutations and liver disease: A case series and review of the

2001;**21**:397-416

s41436-019-0449-6

2008;**294**:1411-1420

2008;**50**:526-532

[17] Khan HH, Mew NA,

[14] Debray D, Corvol H,

1076-1083

[2] Colombo C, Alicandro G. Liver disease in cystic fibrosis: Illuminating the black box. Hepatology. 2019 Apr;**69**(4):1379-1381. DOI: 10.1002/

[3] Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Practice & Research: Clinical Gastroenterology. 2010;**24**:585-592

[4] Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Current Opinion in Gastroenterology.

[5] Guilbault C, Saeed Z, Downey G, et al. Cystic fibrosis mouse model. American Journal of Respiratory Cell and Molecular Biology. 2007;**36**:1-7

[7] Lamireau T, Monnerau S, Martin S, et al. Epidemiology of liver disease in cystic fibrosis: A longitudinal study. Journal of Hepatology.

[8] Colombo C, Russo M, Zazzeron L, Romano G. Liver disease in cystic fibrosis. Journal of Pediatric Gastroenterology and

[9] Elborn J. Cystic fibrosis. Lancet. 2016;**388**(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6

[10] Fiorotto R, Strazzabosco M. Cystic fibrosis-related liver disease: New paradigm for treatment based on pathophysiology. Clinical Liver Disease. 2016;**8**(5):113-116. DOI:

[6] Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology.

1999;**30**(5):1151-1158

2004;**41**:920-925

Nutrition. 2006;**43**:49-55

2018;**34**(3):146-151

Medicine. 2007;**13**:529-536

hep.30255

**References**

*Liver Changes in the Course of Cystic Fibrosis DOI: http://dx.doi.org/10.5772/intechopen.89306*
